Scott Fortune, MD, FAAOA; Meha Fox, MD, FAAOA; Peter Filip, MD, FAAOA If you’ve trained in the last decade, you probably learned to classify chronic rhinosinusitis as one of two things: CRS with nasal polyps or CRS without nasal polyps…
Targeted Molecular Therapies in Allergy and Rhinology
AAOA’s “Targeted Molecular Therapies in Allergy and Rhinology” (Damask C. et al) was published in the Bulletin.
The past decade has seen a rapid expansion in the use of biologic drugs for the treatment of numerous chronic inflammatory diseases.
Biologic drugs are monoclonal antibodies targeting specific Type ll inflammation molecular pathways for a variety of disease entities in the head and neck.
Read the article here:
